Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals Reports Q1 2024 Financial Results and Business Updates
Summary
Regeneron Pharmaceuticals, Inc. reported its financial and operating results for Q1 2024 on May 2, 2024. The company announced a 1% decrease in total revenues to $3.15 billion, primarily due to lower sales of Ronapreve. However, excluding Ronapreve, revenues increased by 7%. Key highlights include a 24% increase in Dupixent global net sales, a 45% increase in Libtayo global net sales, and the authorization of a new $3.0 billion share repurchase program. The company also discussed progress in its clinical pipeline and financial guidance for 2024.
Profitelligence Alerts
Get alerts for REGN
Be first to know when Regeneron Pharmaceuticals, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.
Official SEC Documents
Advertisement